IntroductionChronic spontaneous urticaria (CSU), which has generally replaced the former term chronic idiopathic urticaria (CIU), is defined by the presence of pruritic wheals (hives), angioedema, or both, that persist or recur for a period of at least 6 weeks and do not seem to be induced by any apparent external stimuli. The severity and duration of CSU may vary greatly among patients, while its impact on quality of life can be significant, especially in the presence of concurrent angioedema and when symptoms last for several years or fail to adequately respond to standard therapeutic interventions.According to the latest international guidelines, daily administration of nonsedating, second‐generation, H1‐antihistamines is the “gold‐standard” first‐line treatment of CSU, while dose‐escalation (up to fourfold the licensed daily dose) of H1‐antihistamines is typically followed as a second‐line approach when symptoms persist for more than 2 weeks after the initial treatment course. The use of sedating, first‐generation antihistamines for CSU treatment has been largely abandoned, particularly in Europe. Administration of these drugs (at bedtime only) is nevertheless included, as an alternative to dose advancement of H1‐antihistamines, in the US guidelines, while addition of another second‐generation antihistamine or an H2‐antagonist are among the second‐line treatment options recommended by
International Journal of Dermatology – Wiley
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera